Ignite Creation Date:
2025-12-24 @ 5:23 PM
Ignite Modification Date:
2026-02-02 @ 9:05 AM
Study NCT ID:
NCT03886350
Status:
COMPLETED
Last Update Posted:
2022-06-23
First Post:
2019-03-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Implication of UNconventionaL T Lymphocytes in Cystic Fibrosis (UNLOCk)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003550', 'term': 'Cystic Fibrosis'}], 'ancestors': [{'id': 'D010182', 'term': 'Pancreatic Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D007232', 'term': 'Infant, Newborn, Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D001800', 'term': 'Blood Specimen Collection'}], 'ancestors': [{'id': 'D013048', 'term': 'Specimen Handling'}, {'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D011677', 'term': 'Punctures'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Blood samples Sputum samples'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 62}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-04-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-06', 'completionDateStruct': {'date': '2020-07-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-06-22', 'studyFirstSubmitDate': '2019-03-20', 'studyFirstSubmitQcDate': '2019-03-20', 'lastUpdatePostDateStruct': {'date': '2022-06-23', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-03-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-07-16', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Blood level of Non-Conventional T Lymphocytes', 'timeFrame': '18 months', 'description': 'Blood UTC expressed as % Cluster of Differenciation 3+ (CD3+) lymphocytes (gamme delta T lymphocytes, MAIT cells, Natural Killer T cells)'}, {'measure': 'Sputum level of Non-Conventional T Lymphocytes', 'timeFrame': '18 months', 'description': 'Sputum UTC expressed as % CD3+ lymphocytes (gamme delta T lymphocytes, MAIT cells, Natural Killer T cells)'}], 'secondaryOutcomes': [{'measure': 'UTC activation/inhibition profile', 'timeFrame': '18 months', 'description': 'UTC activation/inhibition based on cell surface markers expression such as Cluster of Differenciation (CD) 69 and Programmed cell death 1 (PD-1)'}, {'measure': 'UTC production of pro-inflammatory cytokines', 'timeFrame': '18 months', 'description': 'Analysis of the level of IL-17, Interferon γ (IFNγ) and Tumor Necrosis Factor α (TNFα) produced by UTC'}, {'measure': 'UTC capacity to mediate cytotoxicity', 'timeFrame': '18 months', 'description': 'UTC cytotoxic profile based on Granzyme B and Cluster of Differenciation (CD) 107a expression'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Unconventional T cells', 'Cystic fibrosis', 'gamma delta T cell', 'Mucosal Associated Invariant T cell', 'Natural Killer T cell'], 'conditions': ['Cystic Fibrosis', 'Innate Immunity', 'Inflammatory Response']}, 'descriptionModule': {'briefSummary': 'Cystic fibrosis (CF) is characterized by a decrease in mucociliary clearance, recurrent infections and airway inflammation. This inflammatory process in airway mucosa is persistent, uncontrolled, but, somewhat paradoxically, ineffective for pathogen clearance. Neutrophils are chronically recruited in the airway mucosa by proinflammatory mediators such as Interleukin (IL)-17. However, mechanisms involved in this dysregulated and persistent immune response are not well understood.\n\nIn this context, a heterogeneous subpopulation of T lymphocytes called "unconventional T cells" (UTC) should deserve greater attention. UTC play a key role in orchestrating the ensuing innate and adaptive immune responses and they are endowed with numerous regulatory and effector properties. UTC mainly establish residency at mucosal sites, including the lung. To date, however, data related to implication and behavior of UTC during cystic fibrosis are extremely limited.\n\nThe hypothesis is that, given UTC properties, their functions and behavior are altered in CF, and thus, these cells could be implicated in persistent inflammation and poor response to infections.\n\nThe objective is to study UTC properties and functions in cystic fibrosis using blood and sputum samples of patients with CF, in correlation with comprehensive clinical and microbiological data.\n\nThe study will enroll adult patients with CF followed-up at University Hospital of Tours, France. For each patient included, blood and sputum samples will be analyzed during 18 months 1/ from routine tests obtained at steady state and 2/ from tests performed during acute exacerbations. UTC will be explored in blood and sputum using flowcytometry approach, to evaluate their relative abundance, activation/inhibition profile and functions (cytokine production and cytotoxic ability). Correlation will be made with clinical status, with longitudinal comparison across the study period for each patient, and comparison with the other patients and healthy volunteers.\n\nThis study will add significant knowledge in CF immunopathology by comprehensively assess UTC presence, functions and activation in CF. Indeed, UTC could be explored for disease progression marker, and, in a long-term perspective, explored for therapeutic interventions aiming at modulating their function (by activating or inhibiting UTC), to reshape lung immune response during CF.', 'detailedDescription': '\\- Clinical and scientific background\n\nCystic fibrosis is characterized by functional abnormalities in the cystic fibrosis transmembrane conductance regulator (CFTR) membrane channel leading to a decrease in mucociliary clearance, recurrent infections and airway inflammation. This inflammatory process in airway mucosa is persistent, uncontrolled, but, somewhat paradoxically, ineffective for pathogen clearance. Neutrophils are chronically recruited in the airway mucosa by proinflammatory mediators such as IL-17, and probably largely contribute to tissue damage. However, up-stream mechanisms involved in this dysregulated and persistent immune response are not well understood.\n\nIn this context, seeking for new candidates that may be involved in this chronic inflammation is critical as there is, to date, no effective treatment to modulate immune response in CF. To address this, a heterogeneous subpopulation of T lymphocytes called "unconventional T cells" (UTC) should deserve greater attention. These cells comprise Natural Killer T (NKT) cells, mucosal associated invariant T cells (MAIT cells) and γδ T cells. The investigators believe these cells could be instrumental for future immune-intervention in CF immunopathology. First, UTC play a key role in orchestrating the ensuing innate and adaptive immune responses. Their pivotal role in mounting host defense during infection have been demonstrated, by the investigators and others, in different experimental models. Notably, their pivotal role for IL-17-driven neutrophil recruitment during acute pulmonary infection is well documented. Second, they are endowed with numerous regulatory and effector properties. Third, UTC mainly establish residency at mucosal sites, including the lung. Last, these cells are already investigated for therapeutic interventions (mainly in oncology, with ongoing phase I and II clinical trials). To date, however, data related to implication and behavior of UTC during cystic fibrosis are extremely limited and preliminary.\n\nThe hypothesis is that, given UTC properties, their functions and behavior are altered in CF, and thus, these cells could be implicated in persistent inflammation and poor response to infections.\n\n\\- Objective of the study: The objective is to study UTC properties and functions in cystic fibrosis using blood and sputum samples of patients with CF, in correlation with comprehensive clinical and microbiological data.\n\n\\- Design:\n\nThis is a prospective exploratory single-center study including adult patients with CF whom follow-up is undertaken at University Hospital of Tours, France.\n\nNumber of participants: 80\n\n\\- Interventions and analysis:\n\nFor each patient included, study duration will be 18 months, during which blood and sputum samples will be analyzed 1/ from routine tests obtained at steady state during annual check-up and follow-up examination and 2/ from tests performed during acute exacerbations treated at the hospital or outpatient. To be enrolled in this study does not add any medical or biological examination compared to the usual follow-up. Each blood or sputum test done during follow-up examination or treating care will lead to supplementary samples for research.\n\nClinical parameters will be collected including clinical status (exacerbation or not), microbial status, pulmonary function test, drugs used like CFTR modulator therapies (lumacaftor ivacaftor) or antibiotics.\n\nUTC will be explored in blood and sputum using flowcytometry approach, to evaluate their relative abundance, activation/inhibition profile and functions (cytokine production and cytotoxic ability). In some cases, intra-cellular staining will be performed to assess cytokine production and/or transcription factor expression. Functions of unconventional T cells will also be performed after ex vivo stimulation on purified population (cell sorting). Cytokine level sand transcriptomic analyses will also be performed on blood samples.Correlation will be made with clinical status, with longitudinal comparison across the study period for each patient, and comparison with the other patients and healthy volunteers.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'Adult patients with cystic fibrosis whom follow-up is undertaken at University Hospital of Tours.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients with a genetic diagnosis of cystic fibrosis\n* Older than 18 years old\n* Be followed-up at University Hospital of Tours\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patient under judicial protection\n* Patient having objected to the processing of his data'}, 'identificationModule': {'nctId': 'NCT03886350', 'acronym': 'UNLOCk', 'briefTitle': 'Implication of UNconventionaL T Lymphocytes in Cystic Fibrosis (UNLOCk)', 'organization': {'class': 'OTHER', 'fullName': 'University Hospital, Tours'}, 'officialTitle': 'Implication of UNconventionaL T Lymphocytes in Cystic Fibrosis', 'orgStudyIdInfo': {'id': 'RIPH3-RNI18 / UNLOCk'}, 'secondaryIdInfos': [{'id': '2019-A00290-57', 'type': 'OTHER', 'domain': 'IdRCB'}]}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients with cystic fibrosis', 'description': 'Patients with CF whom follow-up is undertaken at University Hospital of Tours, France', 'interventionNames': ['Other: blood and sputum samples']}], 'interventions': [{'name': 'blood and sputum samples', 'type': 'OTHER', 'description': 'Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation', 'armGroupLabels': ['Patients with cystic fibrosis']}]}, 'contactsLocationsModule': {'locations': [{'zip': '37044', 'city': 'Tours', 'country': 'France', 'facility': 'Cystic Fibrosis Resource and Competence Center, University Hospital, Tours', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'zip': '37044', 'city': 'Tours', 'country': 'France', 'facility': 'Pulmonology Department, University Hospital, Tours', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}], 'overallOfficials': [{'name': 'Youenn JOUAN, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Hospital, Tours'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University Hospital, Tours', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}